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Daniel Braun, MD,*y Moritz Baquet, MD,*y Steffen Massberg, MD,*y Julinda Mehilli, MD,*y Jörg Hausleiter, MD*yB ioresorbable vascular scaffolds (BVSs) havemany hypothetical advantages over metalstents due to early restoration of vasomotion,
unimpaired imaging with computed tomography, as
well as the maintenance of potential insertion sites
for future bypass grafting.
We report a 66-year-old male patient who pre-
sented with unstable angina. Cardiac catheterization
showed coronary artery disease with a high-grade
stenosis of the proximal right coronary artery (RCA)
(Figure 1A). After predilation with a 3.0-mm balloon,
a 3.25  14-mm novolimus-eluting BVS (DESolve,
Elixir Medical, Sunnyvale, California) was deployed
at 12 atm. Thereafter, post-dilation with a 3.5-mm
noncompliant balloon at 12 atm was performed. At
the end of the procedure, no residual stenosis
or dissection was observed (Figure 1B). Two months
later, the patient presented to the emergency
department with acute chest pain. Coronary angi-
ography did not show restenosis or thrombosis in
the scaffold area (Figure 1C). Optical coherence
tomography (OCT) of the RCA showed partial
malapposition of some struts with incomplete neo-
intimal coverage but without restenosis (minimal/
mean scaffold area, 3.21/5.03 mm2) (Figure 1E). Five
months after BVS implantation, the patient pre-
sented again with unstable angina. Coronary angi-
ography showed subtotal occlusion of the RCA at the
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tion of the neointima leading to restenosis (minimal/
mean scaffold area, 1.01/2.73 mm2) (Figure 1F, Online
Video). We successfully treated the stenosis using
2 drug-eluting metal stents.
The observed partial malapposition with incom-
plete neointimal coverage 2 months after BVS
implantation might partly explain the late scaffold
discontinuity with subsequent strut protrusion,
leading to BVS collapse. One possible reason for late
BVS collapse might be a more rapid and nonuniform
resorption process of this novel novolimus-eluting
BVS leading to fragmentation of the malapposed
scaffold. The reported reduced resorption time of
12 to 24 months for the novolimus-eluting BVS com-
pared with 24 to 48 months for the everolimus-
eluting BVS supports this hypothesis (1).
Although there are numerous pre-clinical and
clinical studies on everolimus-eluting BVSs, data
about performance of a novolimus-eluting BVS are
sparse (2,3). Therefore, further meticulous studies are
warranted for new BVS platforms before widespread
use can be recommended.
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FIGURE 1 Angiography and Optical Coherence Tomography After Implantation of a Bioresorbable Novolimus-Eluting Coronary Scaffold
(A) High-grade stenosis of the right coronary artery caused by thrombus. (B) Angiographic result after treatment with a novolimus-eluting bioresorbable vascular
scaffold (BVS). (C) Angiographic result 2 months after implantation of the scaffold. (D) Angiographic result 5 months after implantation of the BVS. (E) Optical coherence
tomography (OCT) 2 months after BVS implantation (Online Video). (F) OCT 5 months after BVS implantation (Online Video). Red asterisk indicates a protruding strut of
the collapsed scaffold.
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